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Abstract
BACKGROUND: Recently, deleted in breast cancer 1 (DBC1) has been suggested as a poor prognostic indicator of
various human cancers and may possibly have a role as a coactivator of androgen receptor (AR). However, their
roles in lymphoma are still unknown.MATERIALS AND METHODS:We investigated the effect of the expression of
DBC1 and AR in diffuse large B cell lymphoma (DLBCL). Immunohistochemical expression of DBC1 and AR were
evaluated in 101 DLBCL samples by tissue microarray. RESULTS: Positive expression of DBC1 and AR was seen in
73% and 70% of DLBCL, respectively. In total DLBCL patients, DBC1 and AR expression were significantly asso-
ciated with high clinical stage, elevated serum lactate dehydrogenase levels, and high international prognostic
index scores, and they predicted shorter overall survival (OS) and relapse-free survival (RFS) by univariate analysis.
DBC1 expression was also an independent prognostic indicator by multivariate analysis (OS, P = .017; RFS, P =
.004). Especially, both DBC1 and AR expression significantly correlated with shorter OS and RFS in non–germinal
center B cell (non-GCB)–type DLBCL by univariate analysis. In multivariate analysis, DBC1 expression was an
independent prognostic predictor for OS (P = .035) and AR expression significantly correlated with RFS (P =
.005). CONCLUSION: We demonstrate that the expression of DBC1 and AR are significant prognostic indicators
for DLBCL patients, especially for unfavorable non–GCB-type DLBCL.
Translational Oncology (2013) 6, 370–381
Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common type
of lymphoma, accounting for 31% of non-Hodgkin’s lymphoma,
and has aggressive clinical courses [1,2]. However, DLBCL is not
a homogeneous tumor entity and includes various heterogeneous
subgroups. DLBCL has continuously been subclassified according
to the origin of tumor cells, clinicopathologic characteristics, and
alteration of the genetic background of the tumor [2]. Currently,
four distinct subtypes, eight distinct disease entities, and many clinico-
pathologic variants are recognized in the most recent 2008 World
Health Organization classification [2]. However, these are only a
minority of DLBCLs and most DLBCLs are given the diagnostic label
DLBCL, with no additional specification [2]. Therefore, there is a need
to further categorize DLBCL according to the molecular mechanisms
involved, to develop specific treatment modalities, and to better predict
the prognosis of DLBCL patients.
Deleted in breast cancer 1 (DBC1) gene was firstly found by its
deletion in chromosome 8p21 in breast cancer [3]. The characterization
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of DBC1 originally focused on its inhibition of SIRT1 and the conse-
quences this may have in tumor suppressor [4]. However, despite the
original identification of DBC1 by its deletion in breast cancer, over-
expression of DBC1 has been reported in various cancers [5–8]. In ad-
dition, there was simultaneously increased expression of SIRT1 and
DBC1 in advanced human malignant tumors [6,7]. Moreover,
DBC1 represses the tumor suppressor BRCA1 [9] and SUV39H1
methyltransferase [10]. DBC1 could induce cellular proliferation by
positively modulating steroid hormone receptors [11–13]. Depletion
of DBC1 could also induce apoptosis or inhibition of the proliferation
of cancer cells [5,13]. Therefore, there is a possibility that DBC1 has a
proproliferative effect on the tumor cells. However, exact role of DBC1
in tumorigenesis is still unclear.
Androgen receptor (AR) is a member of the nuclear receptor fam-
ily and acts as a ligand-regulated transcription factor. Ligand-bound
AR binds to specific androgen response elements (AREs) and induces
transcription of target genes [14]. In addition, there is evidence that
AR may also induce or inhibit transcription of particular target genes
by interacting with coregulator proteins, termed coactivators or core-
pressors [14]. AR is expressed in many types of normal and malig-
nant cells, regardless of sex [15–18]. In addition to the expression in
prostatic adenocarcinoma, the expression of AR has been reported in
various human malignant tumors, such as breast carcinoma [19],
urothelial carcinoma of the bladder [20], gastric carcinoma [21],
hepatocellular carcinoma [15,22], and lymphoma [23,24].
Currently, a large number of AR coactivators has been reported, and
recently, DBC1 is known to be a novel AR coactivator [12]. DBC1
enhances AR DNA-binding activity and facilitates AR transcriptional
activation [12]. In addition, recent gene microarray data in the Onco-
mine database (www.oncomine.org) of published microarray data
Table 1. Clinicopathologic Variables and the Expression Status of DBC1 and AR in Total DLBCL, Non–GCB-Type DLBCL, and GCB-Type DLBCL.
Characteristics Total DLBCL Non–GCB Type GCB Type
n DBC1+ P AR+ P n DBC1+ P AR+ P n DBC1+ P AR+ P
Age, years
<60 51 37 (73%) .869 37 (73%) .617 28 22 (79%) .738 21 (75%) 1.000 23 15 (65%) .695 16 (70%) .234
≥60 50 37 (74%) 34 (68%) 36 27 (75%) 27 (75%) 14 10 (71%) 7 (50%)
Sex
Male 58 42 (72%) .822 39 (67%) .435 34 27 (79%) .567 26 (76%) .772 24 15 (63%) .371 13 (54%) .173
Female 43 32 (74%) 32 (74%) 30 22 (73%) 22 (73%) 13 10 (77%) 10 (77%)
B symptoms
Absence 82 59 (72%) .535 56 (68%) .360 49 36 (73%) .291 36 (73%) .609 33 23 (70%) .427 20 (61%) .575
Presence 19 15 (79%) 15 (79%) 15 13 (87%) 12 (80%) 4 2 (50%) 3 (75%)
Performance status
0 to 1 74 51 (69%) .102 49 (66%) .137 47 32 (68%) .008 31 (66%) .005 27 19 (70%) .550 18 (67%) .353
2 to 4 27 23 (85%) 22 (81%) 17 17 (100%) 17 (100%) 10 6 (60%) 5 (50%)
Bulky disease
Absence 91 67 (74%) .806 64 (70%) .983 59 45 (76%) .850 44 (75%) .788 32 22 (69%) .698 20 (63%) .915
Presence 10 7 (70%) 7 (70%) 5 4 (80%) 4 (80%) 5 3 (60%) 3 (60%)
Stage
I, II 49 31 (63%) .027 29 (59%) .018 27 17 (63%) .028 17 (63%) .057 22 14 (64%) .536 12 (55%) .247
III, IV 52 43 (83%) 42 (81%) 37 32 (86%) 31 (84%) 15 11 (73%) 11 (73%)
Extranodal sites
0 to 1 76 54 (71%) .381 51 (67%) .221 47 35 (74%) .511 35 (74%) .870 29 19 (66%) .612 16 (55%) .095
≥2 25 20 (80%) 20 (80%) 17 14 (82%) 13 (76%) 8 6 (75%) 7 (88%)
LDH
Normal 54 36 (67%) .038 34 (63%) .015 34 22 (65%) .010 22 (65%) .029 20 14 (70%) .928 12 (60%) .255
Elevated 41 35 (85%) 35 (85%) 27 25 (93%) 24 (89%) 14 10 (71%) 11 (79%)
IPI score
0 to 2 63 41 (65%) .017 38 (60%) .005 36 23 (64%) .007 22 (61%) .004 27 18 (67%) .847 16 (59%) .550
3 to 5 38 33 (87%) 33 (87%) 28 26 (93%) 26 (93%) 10 7 (70%) 7 (70%)
CR
Absence 37 30 (81%) .177 31 (84%) .024 25 21 (84%) .261 22 (88%) .054 12 9 (75%) .503 9 (75%) .265
Presence 64 44 (69%) 40 (63%) 39 28 (72%) 26 (67%) 25 16 (64%) 14 (56%)
Bcl2
Negative 66 49 (74%) .761 47 (71%) .782 40 32 (80%) .402 31 (78%) .551 26 17 (65%) .663 16 (62%) .904
Positive 35 25 (71%) 24 (69%) 24 17 (71%) 17 (71%) 11 8 (73%) 7 (64%)
CD10
Negative 82 60 (73%) .964 58 (71%) .843 64 49 (77%) NA 48 (75%) NA 18 11 (61%) .414 10 (56%) .420
Positive 19 14 (74%) 13 (68%) 0 0 (0%) 0 (0%) 19 14 (74%) 13 (68%)
Bcl6
Negative 46 36 (78%) .300 37 (80%) .041 42 32 (76%) .923 33 (79%) .362 4 4 (100%) .142 4 (100%) .098
Positive 55 38 (69%) 34 (62%) 22 17 (77%) 15 (68%) 33 21 (64%) 19 (58%)
MUM1
Negative 51 33 (65%) .050 32 (63%) .093 22 15 (68%) .252 15 (68%) .362 29 18 (62%) .174 17 (59%) .398
Positive 50 41 (82%) 39 (78%) 42 34 (81%) 33 (79%) 8 7 (88%) 6 (75%)
DLBCL type
GCB 37 25 (68%) .325 23 (62%) .174
Non-GCB 64 49 (77%) 48 (75%)
AR
Negative 30 6 (20%) <.001 16 3 (19%) <.001 14 3 (21%) <.001
Positive 71 68 (96%) 48 46 (96%) 23 22 (96%)
NA indicates not applicable.
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indicate that DBC1 expression was increased in both germinal cen-
ter B cell (GCB) and non-GCB DLBCL types [25,26]. Therefore,
it is suggested that DBC1-mediated regulation of AR could be in-
volved in the pathogenesis of DLBCL. However, there is no report
concerning the expression pattern and the role of DBC1 and AR in
DLBCL. Therefore, here we investigated the expression status of
DBC1 and AR in DLBCL and evaluated their relationship to the
progression and prognosis of DLBCL patients with surgical samples
of DLBCL.
Materials and Methods
Patients and Samples
For this study, we used previously established tissue microarrays
(TMAs) from 104 DLBCL patients diagnosed between December
1995 and April 2007 for whom the expressional status of CD10,
Bcl6, MUM1, and Bcl2 was known [27]. Among the 104 cases in-
cluded in the TMAs, three tissue cores had been exhausted by the
previous study. For these three cases, we reviewed the original tissue
blocks. However, there were no remaining usable samples. There-
fore, we finally included 101 cases in the present study. This study
had local ethics committee approval obtained from the Chonbuk Na-
tional University Hospital’s Institutional Review Board. Informed
consent was provided according to the Declaration of Helsinki.
In the 101 patients included in the present study, 59 patients re-
ceived cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) chemotherapy as an initial regimen. Since 2004, rituximab
was added and 34 patients were treated with rituximab-CHOP
(R-CHOP). Four patients were treated with combined chemotherapy
with other regimens and four patients were treated with radiotherapy.
The patients were grouped according to their age (<60 years vs
≥60 years), sex, stage (I and II vs III and IV), number of extranodal
sites (<2 vs ≥2), serum lactate dehydrogenase (LDH) levels, Eastern
Cooperative Oncology Group (ECOG) performance status (0–1 vs
2–4), presence of bulky disease, presence of B symptoms, presence of
complete response (CR), immunohistochemical expression of Bcl2,
and immunohistochemical subtype of DLBCL by the expression pat-
tern of CD10, Bcl6, and MUM1 (GCB vs non-GCB) [28,29]. We have
used the data for immunohistochemical expression for Bcl2 and immuno-
histochemical subtyping from our previously published report [27]. In
addition, the patients were grouped by international prognostic index
(IPI) scores [low (score of 0–2) vs high (score of 3–5)] [28,30]. Although
there were no data for serum LDH levels in six patients, it was not in-
fluenced by the IPI categorization because the IPI scores without includ-
ing serum LDH levels of six patients were zero, one, or three [27].
Immunohistochemical Staining and Scoring
Immunohistochemical staining was performed by using previously
established TMAs. The antigen retrieval procedure was performed
with a microwave oven for 12 minutes in sodium citrate buffer.
The following markers were used: DBC1 (1:100; Bethyl Laboratories,
Montgomery, TX) and AR (1:50; Santa Cruz Biotechnology, Santa
Cruz, CA; clone N-20). Immunohistochemical scoring was performed
by three pathologists (K.Y.J., S.J.N., and H.S.P.) under a multiviewing
microscope with consensus without knowledge of the clinicopathologic
information. Positivity for DBC1 and AR immunostaining was evalu-
ated to estimate the percentages of positive tumor cells for each marker.
Because it has been reported that DBC1 and AR are expressed primarily
in the nuclei [6,7,23,24], we have evaluated only nuclear staining for
the estimation of positivity for DBC1 and AR immunostaining. The
cases showed nuclear immunoreactivity in more than 30% of tumor
cells scored as positive according to the cutoff value used by others
and us [6,7,27–29].
Figure 1. Immunohistochemical expression of DBC1 and AR in DLBCL. DBC1 and AR are expressed primarily in the nuclei of the tumor
cells. Original magnification, ×400.
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Statistical Analysis
End points of interest were overall survival (OS) and relapse-free sur-
vival (RFS). The follow-up end point was the date of last contact or the
date of death through December 2011. The association between DBC1
and AR expression and other clinicopathologic factors were analyzed us-
ing the Pearson chi-squared test or Pearson correlation coefficient. OS
was measured from the date of diagnosis to the date of death or last con-
tact. Patients who were alive at last contact were treated as censored for
OS analysis. RFS was measured from the date of diagnosis to the date of
relapse, death, or last contact. Patients who were alive at last contact and
who had not recurred were treated as censored for RFS analysis. Univar-
iate and multivariate Cox proportional hazard regression analyses were
performed for the survival analysis. The method by Kaplan and Meier
was used to further illustrate the impact of OS and RFSwhere indicated.
Five- and 10-year survival rates were also calculated. Statistical analyses
were performed using SPSS software (version 18.0). P values less than
.05 were considered statistically significant.
Results
Association of DBC1 and AR Expression with
Clinicopathologic Characteristics of DLBCL
The clinicopathologic features are summarized in Table 1. Re-
sponses to treatments were assessed according to international work-
shop criteria [31]. Among the 101 patients with assessable responses,
Table 2. Five- and 10-Year Survival Rates according to Clinicopathologic Factors and Their Effect on RFS and OS in Total DLBCL Cases by Univariate Analysis.
Characteristics n RFS, HR (95% CI) P OS, HR (95% CI) P 5 Years (%) 10 Years (%)
Age, years
<60 51 1 .346 1 .445 51 51
≥60 50 1.281 (0.765–2.146) 0.810 (0.471–1.392) 42 25
B symptoms
Absence 82 1 .005 1 .025 51 44
Presence 19 2.327 (1.287–4.206) 2.062 (1.097–3.877) 31 31
Performance status
0 to 1 74 1 .001 1 .002 54 46
2 to 4 27 2.597 (1.515–4.451) 2.482 (1.412–4.361) 28 28
Bulky disease
Absence 91 1 .028 1 .179 49 42
Presence 10 2.316 (1.093–4.910) 1.729 (0.778–3.844) 36 36
Stage
I, II 49 1 <.001 1 .001 66 56
III, IV 52 2.785 (1.620–4.788) 23.0 (17.0–29.0) 31 31
Extranodal sites
0 to 1 76 1 .105 1 .407 48 40
≥2 25 1.597 (0.908–2.809) 1.296 (0.702–2.394) 45 45
LDH
Normal 54 1 .002 1 .036 55 40
Elevated 41 2.376 (1.392–4.055) 1.810 (1.041–3.147) 34 34
IPI score
0 to 2 63 1 <.001 1 <.001 58 48
3 to 5 38 3.252 (1.938–5.458) 2.632 (1.530–4.529) 30 30
Treatment
R-CHOP 36 1 .024 1 .143 65 NA
CHOP 60 2.121 (1.103–4.077) 1.649 (0.845–3.219) 43 38
Bcl2
Negative 66 1 .467 1 .499 45 38
Positive 35 0.814 (0.468–1.417) 0.817 (0.454–1.469) 52 52
CD10
Negative 82 1 .102 1 .294 45 40
Positive 19 0.536 (0.254–1.131) 0.668 (0.314–1.420) 54 54
Bcl6
Negative 46 1 .026 1 .004 34 23
Positive 55 0.553 (0.329–0.930) 0.448 (0.258–0.777) 58 58
MUM1
Negative 51 1 .178 1 .323 55 43
Positive 50 1.425 (0.851–2.384) 1.316 (0.764–2.266) 40 40
DLBCL type
GCB 37 1 .005 1 .018 62 62
Non-GCB 64 2.321 (1.289–4.179) 2.132 (1.138–3.995) 39 32
DBC1
Negative 27 1 <.001 1 .001 78 78
Positive 74 4.817 (2.065–11.239) 4.699 (1.867–11.827) 35 28
AR
Negative 30 1 .002 1 .003 69 69
Positive 71 3.026 (1.527–5.997) 3.149 (1.481–6.699) 36 29
DBC1/AR
−/− 24 1 .001 1 .002 76 76
+/− or −/+ 9 1.768 (0.498–6.272) .378 1.468 (0.392–5.490) .569 59 59
+/+ 68 4.413 (1.884–10.340) .001 4.187 (1.663–10.544) .002 34 26
HR indicates hazard ratio; 5 years, 5-year survival rate; 10 years, 10-year survival rate; NA, not applicable; −/−, DBC1−/AR−; +/−, DBC1+/AR−; −/+, DBC1−/AR+; +/+, DBC1+/AR+.
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Figure 2. Kaplan-Meier survival analysis in total DLBCL cases. OS and RFS of IPI risk groups (A) and GCB- versus non–GCB-type DLBCL (B).
Relationship of DBC1 expression (C) and AR expression (D) to OS and RFS.
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Figure 3. Kaplan-Meier survival analysis in non–GCB- and GCB-type DLBCL. Relationship of DBC1 (A) and AR expression (B) to OS and
RFS in non–GCB-type DLBCL. Relationship of DBC1 (C) and AR expression (D) to OS and RFS in GCB-type DLBCL.
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64 patients (63%) had CR and 37 patients (37%) failed to achieve CR.
Nineteen of the 64 patients with CR (30%) relapsed, and 53 patients
(52%) of the total group died. The median follow-up was 61.5 months
(range, 1–191 months). The OS for the entire group of DLBCL
patients was 48%. The 5- and 10-year survival rates for the entire group
were 51% and 45%, respectively. By applying the TMA algorithm for
the immunohistochemical staining for CD10, Bcl6, and MUM1 de-
scribed by Hans et al., 37 (37%) patients were classified as GCB-type
and 64 patients (63%) as non–GCB-type DLBCL [28]. The clinical
features of the total DLBCL patients, GCB-type DLBCL, and non–
GCB-type DLBCL are shown in Table 1.
As it has been previously reported, immunoreactivity of DBC1 in
DLBCL tissues was found primarily in the nuclei [6,7]. Similarly,
AR has been reported to be expressed primarily in the nuclei and
minimally in the cytoplasm in hematopoietic malignant cell lines
[23], AR expression was mainly localized in the nuclei of tumor cells
in DLBCL, and weak cytoplasmic expression was also observed in
some cases. The results of immunohistochemical staining for
DBC1 and AR are shown in Figure 1. Positive expression of
DBC1 and AR was seen in 73% (74/101) and 70% (71/101) of
patients (Table 1). In total DLBCL patients, as shown in Table 1,
DBC1 expression significantly correlated with advanced clinical stage
(P = .027), elevated serum LDH level (P = .038), high IPI score (P =
.017), and AR expression (P < .001). The correlation coefficient
between DBC1 and AR expression was 0.782 (P < .001). The ex-
pression of AR was also significantly correlated with advanced clinical
stage (P = .018), elevated serum LDH level (P = .015), high IPI score
(P = .005), absence of CR (P = .024), and absence of Bcl6 expression
Figure 4. Kaplan-Meier survival analysis DLBCL according to the combined expression pattern of DBC1 and AR. OS and RFS in total
DLBCL (A), non–GCB-type DLBCL (B), and GCB-type DLBCL (C).
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Table 3. Five- and 10-Year Survival Rates according to Clinicopathologic Factors and Their Effect on RFS and OS in Non–GCB- and GCB-Type DLBCL by Univariate Analysis.
Characteristics n RFS, HR (95% CI) P OS, HR (95% CI) P 5 Years (%) 10 Years (%)
Non-GCB
Age, years
<60 29 1 .441 1 .578 32 32
≥60 37 0.791 (0.436–1.435) 1.194 (0.640–2.225) 40 20
B symptoms
Absence 51 1 .032 1 .156 38 25
Presence 15 2.085 (1.064–4.086) 1.689 (0.819–3.480) 33 33
Performance status
0 to 1 49 1 <.001 1 .002 44 31
2 to 4 17 3.685 (1.955–6.946) 2.865 (1.485–5.527) 18 18
Bulky disease
Absence 60 1 .026 1 .520 38 29
Presence 6 3.003 (1.141–7.903) 1.409 (0.496–4.001) 20 20
Stage
I, II 27 1 .004 1 .013 55 36
III, IV 39 2.576 (1.359–4.883) 2.374 (1.204–4.681) 24 24
Extranodal sites
0 to 1 48 1 .488 1 .647 33 20
≥2 18 1.265 (0.650–2.462) 0.840 (0.398–1.773) 47 47
LDH
Normal 35 1 .007 1 .217 43 26
Elevated 28 2.335 (1.267–4.305) 1.497 (0.789–2.842) 30 30
IPI score
0 to 2 37 1 <.001 1 .015 46 31
3 to 5 29 3.213 (1.748–5.906) 2.176 (1.162–4.076) 25 25
Treatment
R-CHOP 19 1 .135 1 .417 45 NA
CHOP 43 1.773 (0.837–3.756) 1.372 (0.640–2.944) 37 29
Bcl2
Negative 41 1 .477 1 .349 35 25
Positive 25 0.797 (0.427–1.489) 0.729 (0.375–1.414 39 39
DBC1
Negative 15 1 .001 1 .006 78 78
Positive 49 6.914 (2.133–22.415) 5.286 (1.623–17.220) 26 18
AR
Negative 16 1 .001 1 .005 69 69
Positive 48 6.154 (2.183–17.347) 4.401 (1.558–12.433) 26 18
DBC1/AR
−/− 13 1 .001 1 .008 75 75
+/− or −/+ 5 0.691 (0.072–6.658) .749 0.518 (0.053–5.096) .573 67 67
+/+ 46 6.818 (2.097–22.160) .001 4.225 (1.301–13.724) .017 24 17
GCB
Age, years
<60 23 1 .057 1 .105 72 72
≥60 15 2.859 (0.971–8.420) 0.382 (0.119–1.223) 41 NA
B symptoms
Absence 34 1 .197 1 .103 66 66
Presence 4 2.307 (0.648–8.220) 2.935 (0.804–10.720) 25 25
Performance status
0 to 1 28 1 .321 1 .137 67 67
2 to 4 10 1.729 (0.586–5.100) 2.359 (0.761–7.310) 45 45
Bulky disease
Absence 33 1 .144 1 .072 64 64
Presence 5 2.599 (0.723–9.344) 3.337 (0.899–12.381) 40 40
Stage
I, II 22 1 .060 1 .024 79 79
III, IV 16 2.696 (0.958–7.584) 3.904 (1.198–12.724) 34 34
Extranodal sites
0 to 1 30 1 .098 1 .036 69 69
≥2 8 2.482 (0.847–7.275) 3.326 (1.085–10.197) 33 33
LDH
Normal 21 1 .085 1 .074 72 72
Elevated 14 2.681 (0.873–8.230) 2.786 (0.907–8.557) 38 38
IPI score
0 to 2 28 1 .082 1 .029 70 70
3 to 5 10 2.507 (0.890–7.064) 3.400 (1.136–10.170) 36 36
Treatment
R-CHOP 17 1 .229 1 .471 81 NA
CHOP 17 2.284 (0.595–8.771) 1.684 (0.408–6.956) 55 55
Bcl2
Negative 27 1 .476 1 .773 57 57
Positive 11 0.630 (0.177–2.241) 0.826 (0.226–3.016) 73 73
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(P = .041). In non–GCB-type DLBCL, DBC1 expression showed
significant correlation with high ECOG performance status (P =
.008), advanced clinical stage (P = .028), elevated serum LDH level
(P = .010), and high IPI score (P = .007). AR expression also showed
significant correlation with high ECOG performance status (P =
.005), elevated serum LDH level (P = .010 and P = .029, respec-
tively), and high IPI score (P = .004). However, there were no clinico-
pathologic factors that have statistically significant association with
DBC1 or AR expression in GCB-type DLBCL. Of particular note,
the correlation between DBC1 expression and AR expression was
significant in both non–GCB-type (P < .001) and GCB-type (P <
.001) DLBCL.
Expression of DBC1 and AR in DLBCL Was Correlated
with Reduced RFS and OS according to Univariate Analysis
Univariate analysis of the expression of DBC1 and AR and its
relationship to RFS and OS are shown in Table 2. For DLBCL in
general, presence of B symptoms, high ECOG performance status,
high clinical stage, increased serum LDH, high IPI score, absence
of Bcl6 expression, and non–GCB-type DLBCL predicted shorter
OS and RFS (Figure 2, A and B). DBC1 expression predicted shorter
OS (P = .001) and RFS (P < .001; Figure 2C ). Tumors expressing
AR were associated with both significantly shorter OS (P = .003) and
RFS (P = .002; Figure 2D). The 5- and 10-year survival rates of
DBC1-negative patients were both 78%. In contrast, the patients
with DBC1 expression had a 35% 5-year survival rate and a 28%
10-year survival rate. Similarly, the patients with AR expression
had a 29% 10-year survival rate, and AR-negative patients had a
69% 10-year survival rate. The 5-year survival rate of R-CHOP–treated
patients (65%) was longer than that of CHOP-treated patients (43%).
Although, there was no difference in OS between R-CHOP– and
CHOP-treated patients (P = .143), R-CHOP–treated patients showed
favorable RFS compared with CHOP-treated patients (P = .024). In
our DLBCL population, the follow-up duration was different between
those two groups since rituximab was added in treatment regimens of
DLBCL after 2004. The mean follow-up duration of the R-CHOP–
treated group was 34 months (range, 1–92 months), while it was
59 months (range, 2–191 months) for the CHOP-treated group.
Therefore, when we did survival analysis in the patients with less than
93 months of follow-up, R-CHOP–treated patients showed signifi-
cantly longer OS (P < .001) and RFS (P < .001) than those of the
CHOP-treated patients. In these patient groups, DBC1 expression also
predicted shorter OS (P = .001) and RFS (P = .001) and AR expression
also predicted shorter OS (P = .003) and RFS (P = .004).
In non-GCB type, high ECOG performance status, high clinical
stage, high IPI score, DBC1 expression, and AR expression predicted
shorter OS and RFS (Figure 3, A and B). In GCB type, high clinical
stage, high number of extranodal involvement, and high IPI score
predicted shorter OS. However, there was no factor significantly
associated with RFS in GCB type. Only the expression of DBC1
was a possible predictor of RFS (P = .064; Figure 3, C and D). When
separately considering DLBCL patients with low or high IPI scores,
Table 4. Multivariate Cox Regression Analysis for RFS and OS in Total DLBCL, Non–GCB Type, and GCB Type.
Characteristics RFS, HR (95% CI) P OS, HR (95% CI) P
Total DLBCL
Stages III and IV (versus I and II) 2.775 (1.456–5.290) .002 2.703 (1.450–5.037) .002
DBC1 positive (versus negative) 3.909 (1.536–9.950) .004 3.137 (1.230–8.000) .017
Bcl6 positive (versus negative) 0.789 (0.422–1.473) .456 0.440 (0.243–0.795) .007
Performance status 2 to 4 (versus 0–1) 2.309 (1.296–4.113) .005 1.811 (1.006–3.261) .048
Bulky disease presence (versus absence) 2.737 (1.246–6.011) .012 2.528 (1.091–5.855) .030
Non-GCB
Stages III and IV (versus I and II) 2.234 (1.166–4.280) .015 2.319 (1.160–4.636) .017
AR positive (versus negative) 4.541 (1.562–13.197) .005 1.899 (0.455–7.925) .379
DBC1 positive (versus negative) 2.368 (0.508–11.044) .273 3.695 (1.098–12.437) .035
Performance status 2 to 4 (versus 0–1) 2.363 (1.232–4.532) .010 2.007 (1.020–3.948) .044
GCB
Stages III and IV (versus I and II) 4.166 (1.258–13.800) .020
DBC1 positive (versus negative) 3.663 (0.723–18.547) .117
HR indicates hazard ratio.
Table 3. (continued )
Characteristics n RFS, HR (95% CI) P OS, HR (95% CI) P 5 Years (%) 10 Years (%)
DBC1
Negative 12 1 .160 1 .105 80 80
Positive 25 2.513 (0.696–9.072) 3.573 (0.765–16.681) 51 51
AR
Negative 14 1 .876 1 .501 68 68
Positive 23 0.921 (0.326–2.599) 1.502 (0.459–4.912) 56 56
DBC1/AR
−/− 11 1 .285 1 .440 78 78
+/− or −/+ 4 3.652 (0.731–18.255) .115 2.761 (0.456–16.703) .269 50 50
+/+ 22 1.749 (0.470–6.506) .404 2.636 (0.565–12.293) .217 54 54
HR indicates hazard ratio; 5 years, 5-year survival rate; 10 years, 10-year survival rate; NA, not applicable; −/−, DBC1−/AR−; +/−, DBC1+/AR−; −/+, DBC1−/AR+; +/+, DBC1+/AR+.
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DBC1 expression predicted significantly worse OS and RFS within
both low IPI (OS, P = .013; RFS, P = .023) and high IPI (OS, P =
.036; RFS, P = .033) categories. AR expression also predicted signif-
icantly shorter OS (P = .028) within the low IPI category but not in
high IPI category.
There was significant correlation between DBC1 and AR expres-
sion, and positive correlative roles between these two molecules in
cell biology have been suggested. Therefore, we performed further
survival analysis with the combined expression patterns of DBC1
and AR. As shown in Figure 4, DLBCL coexpressing DBC1 and
AR (DBC1+/AR+ group) showed the most unfavorable OS and
RFS compared with other subgroups in total DLBCL (log rank:
OS, P = .001; RFS, P < .001) and non-GCB type (log rank: OS,
P = .002; RFS, P < .001). The 10-year survival rate of the DBC1+/
AR+ group was 26% in total DLBCL and only 17% in non-GCB type.
In contrast, the 10-year survival rate of DBC1−/AR− group was 76%
in total DLBCL and 75% in non-GCB type (Table 2).
Expression of DBC1 in DLBCL Was an Independent Prognostic
Factor for Worse Survival Outcome by Multivariate Analysis
The variables significantly correlated with OS or RFS by univari-
ate analysis were included in multivariate analysis for OS or RFS.
The variables included in multivariate analysis for OS and RFS of
total DLBCL were presence of B symptoms, ECOG performance
status, presence of bulky disease, stage, serum LDH levels, IPI score,
immunohistochemical subtype of DLBCL, and the expression of
BCL6, DBC1, and AR. For total DLBCL, stage, ECOG perfor-
mance status, presence of bulky disease, and DBC1 expression were
independent prognostic factors significantly associated with both OS
and RFS. The patients with DBC1 expression had a 3.137-fold
[95% confidence interval (CI), 1.23–8.0] greater risk of lower OS
(P = .017) and a 3.909-fold (95% CI, 1.536–9.95) greater risk of
lower RFS (P = .004) than those who did not express DBC1.
DBC1 expression was also a prognostic factor significantly associated
with OS in non–GCB-type DLBCL. The patients having DBC1-
expressing tumors had a 3.695-fold (95% CI, 1.098–12.437) greater
risk of death than those who did not express DBC1 (P = .035). In
non–GCB-type DLBCL, AR expression was significantly associated
with lower RFS (P = .005) by multivariate analysis. However, in
GCB–type DLBCL, only the clinical stage of DLBCL was an in-
dependent predictor of OS (P = .020). Other factors did not associ-
ate with OS or RFS by multivariate analysis in GCB–type DLBCL
(Tables 3 and 4).
Discussion
In the present study, we investigated the possible clinical significance
of the expression of DBC1 and AR in DLBCL patients. Of signifi-
cance, positive expression of DBC1 and AR were seen in 73% (74/
101) and 70% (71/101) of patients, respectively, and the expression
of DBC1 and AR showed significant correlation. In addition, the
expression pattern of DBC1 and AR were significantly associated
with high clinical stage, elevated serum LDH level, and high IPI score,
and they both predicted shorter OS and RFS in DLBCL. In multi-
variate analysis, DBC1 expression was an independent prognostic
indicator of OS and RFS in total DLBCL patients. In non–GCB-type
DLBCL, DBC1 expression was an independent prognostic indicator
of OS and AR expression significantly correlated with RFS. These
findings suggest that DBC1 and AR may be involved in the progres-
sion of DLBCL and their expression is a clinically significant prog-
nostic indicator in DLBCL patients, especially in non-GCB type. In
line with this study, DBC1 was also a poor prognostic indicator of
human malignant tumors, such as breast cancer [6], gastric carcinoma
[7], and esophageal squamous cell carcinoma [5]. However, the ex-
pression of DBC1 and AR in lymphoid organs are underestimated
and there is no report on the clinical significance of their expression
in lymphoma. Therefore, this is the first report evaluating the clinico-
pathologic significance of DBC1 and AR in human DLBCL.
In this report, we present DBC1 as an indicator of poor prognosis
of DLBCL. Consistently, DBC1 predicted poor survival of the var-
ious cancer patients [5–7]. A recent report showed that DBC1 en-
hances AR DNA-binding activity and facilitates AR transcriptional
activation [12]. In this study, the expression of DBC1 and AR were
significantly correlated in DLBCL. Sixty-eight of 74 (96%) cases of
DBC1-positive DLBCL were positive for AR. In addition, both AR
and DBC1 expression were significantly associated with poor prog-
nosis of DLBCL patients. Especially, DLBCL coexpressing DBC1
and AR had shorter survival times, and DLBCL expressing neither
of the two showed the longest survival time. In the DBC1−/AR−
group, there was no difference in the 10-year survival rates between
GCB (78%) and non-GCB type (75%). In contrast, the 10-year
survival rate was significantly deferent between GCB (54%) and non-
GCB type (17%) in the DBC1+/AR+ group. In addition, our pre-
vious report also indicated SIRT1 as an indicator of poor prognosis
of DLBCL despite the opposing roles of SIRT1 and DBC1 [27]. There
was also a high correlative association between DBC1 and SIRT1 ex-
pression [6,7]. Therefore, we analyzed the correlation between DBC1
and SIRT1 with previously reported SIRT1 expression in DLBCL [27]
and DBC1 expression in this study. In this analysis, they were also
significantly correlated (P = .003). Sixty of 74 (81%) cases of DBC1-
expressing DLBCL showed SIRT1 positivity. Therefore, our results
suggest that cooperation of DBC1 with AR, as an AR coactivator,
may be involved in the progression of DLBCL rather than having a
role as an SIRT1 inhibitor.
AR is a ligand-regulated transcription factor [14] and it is distrib-
uted in various normal and malignant cells [15–18]. AR expression
in human hematopoietic malignancies, including leukemic cells [32],
non-Hodgkin’s lymphoma cells [23,24], and Hodgkin’s lymphoma
cells [23], has also been demonstrated. Recent data in the Oncomine
microarray database also showed increased AR expression in DLBCL
[33]. The expression rate of AR in human tissues was reported to vary
from 12.9% to 100% according to the scoring methods [15–22,
34–37]. In our study, 70% (71 of 101) of DLBCL expressed AR
and that was relatively higher than expectation. Interestingly, AR
expression was significantly associated with CR rate. AR-negative
DLBCL had an 84% CR rate, while AR-positive DLBCL showed
only a 63% CR rate. Similarly, AR-negative breast cancer patients
(24.5%) showed a higher CR rate following neoadjuvant chemo-
therapy than AR-positive (12.8%) patients [38]. In urothelial car-
cinoma, AR expression decreased the chemosensitivity of tumor
cells and increased the migration of tumor cells [39]. In addition,
AR promoted hepatic tumorigenesis by increasing cellular oxidative
stress and DNA damage, as well as suppressing p53 [15]. Moreover,
a recent report suggested that androgen therapy may have a benefit
in the treatment of AR-expressing ovarian tumors based on the
finding that the expression of AR decreased when the tumor was
exposed to platinum-based chemotherapy [40]. Therefore, it has
been suggested that AR expression may be involved in both progres-
sion of DLBCL and resistance to chemotherapeutic agents. In our
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previous report, SIRT1 expression was also associated with low a
CR rate in DLBCL patients [27]. Therefore, when we analyzed
the correlation of AR and SIRT1 expression, there was significant
correlation between the expression of AR and SIRT1 (P = .003).
Fifty-eight of 71 (82%) cases of AR-expressing DLBCL were also
positive for SIRT1. Therefore, there is a possibility that AR-
mediated chemoresistance may be related to SIRT1 expression in
tumor cells. However, the exact role of AR in human malignant
tumors is still unclear and further study is needed. The clinical sig-
nificance of AR expression in malignant tumors has also been
addressed in several conflicting reports. In some reports, cancer cells
showed higher AR expression than in normal tissues [15,34,41] and
AR expression was correlated with poor clinical courses in prostatic
cancer [34], male breast cancer [19], gastric carcinoma [21], and
hepatocellular carcinoma [22]. In contrast, other reports have
shown that AR expression was associated with favorable clinical
course [18,20,35–37] or did not affect the clinical course [16,17].
Currently, most DLBCL patients are treated with R-CHOP–
based chemotherapy. After addition of rituximab to CHOP chemo-
therapy, the survival of patients improved significantly [42]. In our
patient population, R-CHOP–treated patients showed significantly
longer RFS than CHOP-treated patients. When we did survival anal-
ysis in the follow-up of 67 matched patients, R-CHOP–treated pa-
tients showed significantly longer OS and RFS. Accordingly, because
the recent chemotherapeutic regimens are based on R-CHOP, we
performed additional survival analysis with the incorporation of the
DBC1 and AR expression data within the R-CHOP–treated patients.
In the R-CHOP–treated subgroup, DBC1 expression predicted
shorter OS (P = .006) and RFS (P = .027) despite a small patient
group (n = 34). AR expression was also a predictor of OS (P =
.051) and RFS (P = .072), although with borderline significance.
Although DLBCL is clustered as one diagnostic category, DLBCL
is a heterogeneous group composed of B cells with various genetic,
molecular, and developmental backgrounds [1,2]. One of the classi-
fications of DLBCL that can be done easily in clinical practice is the
division of DLBCL into GCB and non-GCB subgroups by immuno-
histochemical staining. GCB versus non-GCB subgrouping of
DLBCL significantly affected the prognosis of the patients [27,28].
According to the Hans algorithm, the lack of germinal center cell
phenotype is associated with poor prognosis [28]. Our results also
demonstrated the non-GCB group as having a poor prognosis. In
addition, despite the improvement of an outcome of both GCB
and non-GCB groups with R-CHOP chemotherapy, the non-
GCB immune phenotype remains a poor prognostic factor [43]. In
our 36 patients treated with R-CHOP chemotherapy, the non-GCB
group had shorter OS than the GCB group (P = .081; 5-year survival
rates: GCB, 70%; non-GCB, 42%; mean survival time: GCB, 61 ±
25 months; non-GCB, 50 ± 30 months). Interestingly, in our study,
both DBC1 and AR expression significantly correlated with shorter
OS and RFS in the non-GCB subtype. Therefore, we suggest that
DBC1 and AR targeted therapy could be a good additional stratagem
for the treatment of DLBCL patients with poor prognosis.
Taken together, our findings suggest that the DBC1-AR pathway
may have a role in the progression of DLBCL and the expression of
DBC1 and AR are clinically significant prognostic indicators for
DLBCL patients, especially those with non–GCB-type DLBCL. In
addition, our findings suggest that modulation of DBC1- and AR-
related steroid hormone pathways could be new therapeutic targets
for the treatment of DLBCL.
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